SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : momo-T/FIF -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (11134)6/7/2017 9:10:26 PM
From: Miljenko Zuanic  Respond to of 12215
 
MGL-3196 and VK2809 are sufficiently different (structure) to eliminate any overlapping IP issue. Regards the activity, both P2 trial are due to completion at similar time-frame, so it will be interesting to compare activity/safety. MGL have single arm drug, VK have 4-arms against placebo, so MGL may have stronger case IF positive.



To: tuck who wrote (11134)6/19/2017 2:12:36 PM
From: Miljenko Zuanic  Respond to of 12215
 
This may be good for their drug, but I will not bet the horse.
cell.com


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News